Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TriSalus Life Sciences, Inc. (Nasdaq: TLSI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. TriSalus identifies itself in these filings as an emerging growth company and an oncology-focused medical technology business built around its Pressure-Enabled Drug Delivery (PEDD) platform and investigational immunotherapy, nelitolimod.
Through Forms 8-K, TriSalus reports material events such as quarterly financial results, business updates, changes in directors, compensation decisions and capital structure actions. Recent 8-K filings describe press releases announcing results for quarters ended June 30 and September 30, 2025, along with revenue performance driven by sales of the TriNav system. Other 8-Ks detail an exchange offer and consent solicitation related to Series A Convertible Preferred Stock, amendments to the certificate of designations, and subsequent conversion of preferred shares into common stock.
These filings also document governance and compensation matters, including director resignations and adjustments to executive base salary and performance-based stock option grants that vest upon achieving specified revenue thresholds. Together, they provide insight into how TriSalus manages its capital structure, aligns management incentives and responds to financing needs while advancing its PEDD-based devices and clinical-stage immunotherapy.
On Stock Titan, SEC documents for TLSI are updated as they are made available through EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, operating results, capital structure changes and governance items, and make it easier to interpret the implications of each report. This allows users to quickly understand what TriSalus is disclosing about its operations, financial condition and strategic decisions without reading every page in detail.
TriSalus Life Sciences, Inc. director Michael P. Stansky reported receiving a grant of stock options to buy 92,537 shares of common stock at an exercise price of $4.91 per share. The options vest in three equal annual installments starting on February 4, 2027, contingent on his continued service with the company.
TriSalus Life Sciences director Michael P. Stansky reported his existing ownership in a new Form 3 filing. He beneficially owns 543,232 shares of TriSalus common stock and a warrant exercisable for 827,500 shares of common stock at an exercise price of $11.50 per share, expiring on August 10, 2028.
The filing also reports 82,500 shares of common stock owned by Skyview Investments LLC, where Stansky is the managing member and exercises voting and dispositive power. All of these securities were acquired before he became a director, effective February 4, 2026.
TriSalus Life Sciences, Inc. announced a board change, with Dr. Arjun “JJ” Desai resigning as a director effective February 3, 2026. His resignation is stated to be unrelated to any disagreement over the company’s operations, policies, or practices.
The company appointed veteran healthcare investor Michael P. Stansky to its Board of Directors effective February 4, 2026. He will serve on the Audit Committee, Compensation Committee, and Science and Technology Committee. TriSalus highlighted his 40 years of investment management and healthcare experience, including senior roles at Tudor Investment Corporation and Wellington Management.
TriSalus Life Sciences, Inc. filed a current report to note that it issued a press release with preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with 2026 revenue guidance. The company attached this press release as Exhibit 99.1 and incorporated it by reference for informational purposes. The report also clarifies that the press release and related information are being furnished rather than filed, which limits their exposure to certain securities law liabilities.
TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief of Research. On November 24, 2025, the officer received 40,000 shares of common stock as a restricted stock unit award at a price of $0, increasing beneficial ownership to 166,599 common shares held directly. These RSUs vest in four equal annual installments starting November 24, 2025, conditioned on continued employment.
The officer was also granted an employee stock option to purchase 80,000 shares of common stock at an exercise price of $5.55 per share, expiring on November 23, 2035. One-fourth of the option vests on November 24, 2026, with the remaining portion vesting monthly thereafter, also subject to continued employment.
TriSalus Life Sciences, Inc. (TLSI) reported equity awards to its Chief of Clinical Operations on a Form 4. The officer received 50,000 shares of common stock as a restricted stock unit (RSU) award on November 24, 2025, which will vest in four equal annual installments starting on that date, conditioned on continued employment at each vesting date.
The officer was also granted an employee stock option to buy 100,000 shares of common stock at an exercise price of $5.55 per share. One-fourth of the option shares vest on the one-year anniversary of the November 24, 2025 vesting commencement date, and the remaining shares vest monthly in equal installments over the following three years, also subject to continued employment. Following these grants, the reporting person beneficially owned 100,571 shares of common stock directly and 463,750 derivative securities in the form of options.
TriSalus Life Sciences (TLSI) reported new equity awards to its CEO and President, Mary Szela, in a Form 4 filing. She received 125,000 performance stock units (PSUs) on 02/13/2024 that vest upon achieving or exceeding $50 million of revenue over any 12‑month period ending on or before February 28, 2027. On 11/24/2025 she was granted 125,000 restricted stock units that vest in four equal annual installments starting November 24, 2025.
Also on 11/24/2025, she received 300,000 additional PSUs tied to achieving or exceeding $75 million of revenue over any 12‑month period ending on or before December 31, 2027, with 150,000 vesting upon achievement and 150,000 vesting one year later. She was further granted an option to buy 250,000 shares at $5.55 per share, expiring on 11/23/2035, vesting over four years. After these transactions, she beneficially owns 742,802 common shares and 1,578,182 derivative securities directly.
TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief Regulatory Officer on a Form 4. On November 24, 2025, the officer received 50,000 restricted stock units payable in common stock at a price of $0, with the award vesting in four equal annual installments starting November 24, 2025, subject to continued employment. The filing also discloses an employee stock option to purchase 100,000 shares of common stock at an exercise price of $5.55 per share, with one-fourth vesting on the one-year anniversary of November 24, 2025 and the remainder vesting monthly over three years, also conditioned on continued employment.
After these transactions, the officer beneficially owns 127,640 shares of common stock directly and 323,782 derivative securities, reflecting equity-based incentives tied to future service.
TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief Commercial Officer on a Form 4. On November 24, 2025, the officer received 60,000 shares of common stock in the form of restricted stock units at a price of $0, bringing direct beneficial ownership of common stock to 113,854 shares after the transaction.
The same day, the officer was also granted an employee stock option to purchase 120,000 shares of common stock at an exercise price of $5.55 per share, with 408,937 derivative securities beneficially owned following the transaction. The RSUs vest in four equal annual installments starting on November 24, 2025, and the option vests over four years, with one-fourth vesting on the first anniversary of the vesting commencement date and the remainder vesting monthly through November 23, 2035, in each case subject to continued employment.
TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its chief financial officer in a Form 4 filing. On 11/24/2025, the officer received 65,000 shares of common stock as a restricted stock unit (RSU) award at a price of $0, increasing beneficial ownership of common stock to 265,000 shares held directly.
The filing also reports an employee stock option grant to buy 130,000 shares of common stock at an exercise price of $5.55 per share, expiring on 11/23/2035. The RSU award vests in four equal annual installments starting 11/24/2025, while one-fourth of the option vests on the one-year anniversary of 11/24/2025 and the remaining shares vest monthly over the following three years, in each case subject to continued employment. Following this option grant, the officer beneficially owns 668,899 derivative securities directly.